Primary Care Diabetes
Volume 2, Issue 2 , Pages 67-72 , June 2008

Recent advances in the genetics of diabetes

Received 2 November 2007 ,Accepted 18 December 2007.

References 

  1. Stride A, et al. Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann. Med. 2002;34(3):207–216
  2. Pearson ER, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362(9392):1275–1281
  3. Shepherd M, et al. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care. 2003;26(11):3191–3192
  4. Pearson ER, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4(4):pe118
  5. Fajans SS, et al. Macrosomia and neonatal hypoglycaemia in RW pedigree subjects with a mutation (Q268X) in the gene encoding hepatocyte nuclear factor 4alpha (HNF4A). Diabetologia. 2007;50(12):2600–2602
  6. Iafusco D, et al. Permanent diabetes mellitus in the first year of life. Diabetologia. 2002;45(6):798–804
  7. Edghill EL, et al. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes. 2006;55(6):1895–1898
  8. Shield JP. Neonatal diabetes: how research unravelling the genetic puzzle has both widened our understanding of pancreatic development whilst improving children's quality of life. Horm. Res. 2007;67(2):77–83
  9. Gloyn AL, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 2004;350(18):1838–1849
  10. Proks P, et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.. Hum. Mol. Genet. 2006;15(11):1793–1800
  11. Babenko AP, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 2006;355(5):456–466
  12. Sagen JV, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes. 2004;53(10):2713–2718
  13. Pearson ER, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 2006;355(5):467–477
  14. Slingerland AS, et al. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia. 2006;49(11):2559–2563
  15. Altshuler D, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 2000;26(1):76–80
  16. Gloyn AL, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52(2):568–572
  17. Sandhu MS, et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat. Genet. 2007;39(8):951–953
  18. Gudmundsson J, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 2007;39(8):977–983
  19. Grant SF, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 2006;38(3):320–323
  20. Lyssenko V, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 2007;117(8):2155–2163
  21. Schafer SA, et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia. 2007;50(12):2443–2450
  22. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat. Rev. Genet. 2007;8(9):657–662
  23. Pascoe L, et al. Common variants of the novel type 2 diabetes genes, CDKAL1 and HHEX/IDE, are associated with decreased pancreatic {beta}-cell function. Diabetes. 2007;56(12):3101–3104
  24. Grarup N, et al. Studies of association of variants near the HHEX, CDKN2A/B and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects validation and extension of genome-wide association studies. Diabetes. 2007;56(12):3105–3111
  25. Frayling TM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894
  26. Bottini N, et al. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol. 2006;18(4):207–213
  27. Vella A, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 2005;76(5):773–779
  28. Smyth DJ, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet. 2006;38(6):617–619
  29. Todd JA, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 2007;39(7):857–864
  30. Weedon MN, et al. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med. 2006;3(10):pe374
  31. Pearson ER, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes. 2007;56(8):2178–2182

PII: S1751-9918(07)00183-0

doi: 10.1016/j.pcd.2007.12.005

Primary Care Diabetes
Volume 2, Issue 2 , Pages 67-72 , June 2008

Article Tools

* Image Usage & Resolution